Astria Therapeutics Inc (ATXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Astria Therapeutics Inc (ATXS) has a cash flow conversion efficiency ratio of -0.138x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.30 Million) by net assets ($233.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Astria Therapeutics Inc (ATXS) market capitalisation for the company's overall valuation and market capitalisation.
Astria Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Astria Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Astria Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Astria Therapeutics Inc ranked by their cash flow conversion efficiency. See ATXS operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bomesc Offshore Engineering Co
SHG:603727
|
0.022x |
|
Depo Auto Parts Industrial Co Ltd
TW:6605
|
0.051x |
|
Yalla Group Ltd
NYSE:YALA
|
0.007x |
|
Arrow Financial Corporation
NASDAQ:AROW
|
0.035x |
|
Bain Capital Specialty Finance Inc
NYSE:BCSF
|
0.021x |
|
HELL.UNSP.ADR A1 DL-0001
F:1MO
|
0.050x |
|
Lightwave Logic Inc
NASDAQ:LWLG
|
-0.050x |
|
Zhejiang Vie Science & Technology Co Ltd
SHE:002590
|
0.045x |
Annual Cash Flow Conversion Efficiency for Astria Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Astria Therapeutics Inc from 2012 to 2024. View Astria Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $319.26 Million | $-81.21 Million | -0.254x | +9.65% |
| 2023-12-31 | $243.12 Million | $-68.44 Million | -0.282x | -43.06% |
| 2022-12-31 | $221.22 Million | $-43.53 Million | -0.197x | +20.17% |
| 2021-12-31 | $122.31 Million | $-30.15 Million | -0.247x | +69.14% |
| 2020-12-31 | $40.67 Million | $-32.48 Million | -0.799x | -7.39% |
| 2019-12-31 | $35.72 Million | $-26.57 Million | -0.744x | -10.76% |
| 2018-12-31 | $34.94 Million | $-23.46 Million | -0.672x | +70.49% |
| 2017-12-31 | $11.79 Million | $-26.84 Million | -2.276x | -101.45% |
| 2016-12-31 | $29.09 Million | $-32.86 Million | -1.130x | -91.46% |
| 2015-12-31 | $50.49 Million | $-29.79 Million | -0.590x | -311.17% |
| 2014-12-31 | $-73.05 Million | $-20.41 Million | 0.279x | -10.91% |
| 2013-12-31 | $-52.18 Million | $-16.37 Million | 0.314x | +108.63% |
| 2012-12-31 | $4.29K | $-15.58K | -3.634x | -- |
About Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also devel… Read more